The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: Focus on Severe Cutaneous Adverse Reactions
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The International Congress on Cutaneous Adverse Drug Reactions (cADR) was first held in 1994. This important scientific event is the world’s largest meeting on this subject. Registration is open to everyone and anyone can submit papers for consideration.
The 8th International Congress on Cutaneous Adverse Drug Reactions was held in Taipei, Taiwan, on 16–17 November 2013. The location was of special significance, not only because of the important scientific contribution of the Taiwanese research group to the field, but also because it was the first time the congress was held outside of Europe.
The meeting was organized by the Taiwanese Dermatological Association and the Chang Gung Memorial Hospital, Department of Dermatology, Taipei, Taiwan, and immediately followed the World SCAR (Severe Cutaneous Adverse Drug Reactions) meeting at the same venue. The scientific programme was drawn up by an international committee appointed by the Chair, Dr. Wen-Hung Chung. The full programme ...
- Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225–30. CrossRef
- Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343–50. CrossRef
- Roujeau JC, Bricard G, Nicolas JF. Drug-induced epidermal necrolysis: important new piece to end the puzzle. J Allergy Clin Immunol. 2011;128:1277–8. CrossRef
- Brockow K, Romano A. Skin tests in the diagnosis of drug hypersensitivity reactions. Curr Pharm Des. 2008;14:2778–91. CrossRef
- Kano Y, Inaoka M, Sakuma K, Shiohara T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome. Toxicology. 2005;209:165–7. CrossRef
- Kang S, Cho S, Chung JH, Hammerberg C, Fisher GJ, Voorhees JJ. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166:1691–9. CrossRef
- Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–79. CrossRef
- Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A. 2012;109:9959–64. CrossRef
- Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev. 2013;34:15–38.
- Vocanson M, Achachi A, Mutez V, Cluzel-Tailhardat M, Varlet BL, Rozières A, et al. Human T cell priming assay: depletion of peripheral blood lymphocytes in CD25(+) cells improves the in vitro detection of weak allergen-specific T cells. EXS. 2014;104:89–100.
- Pichler WJ. The p-i Concept: pharmacological interaction of drugs with immune receptors. World Allergy Organ J. 2008;1:96–102. CrossRef
- Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60–8. CrossRef
- Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, et al.; RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197–204.
- Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39:594–601. CrossRef
- Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486. CrossRef
- Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–9. CrossRef
- Ushigome Y, Kano Y, Hirahara K, Shiohara T. Human herpesvirus 6 reactivation in drug-induced hypersensitivity syndrome and DRESS validation score. Am J Med. 2012;125:e9–10. CrossRef
- Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009;182:8071–9. CrossRef
- Criado PR, Criado RF, Avancini Jde M, Santi CG. Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol. 2012;87:435–49.
- Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68:721–8. CrossRef
- The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: Focus on Severe Cutaneous Adverse Reactions
Volume 37, Issue 6 , pp 459-464
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
- 2. Department of Dermatology, Ha’emek Medical Center, Afula, Israel
- 3. Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospitals, Taipei, Linkou, and Keelung, Taiwan
- 4. College of Medicine, Chang Gung University, Taoyuan, Taiwan
- 5. Division of Clinical Pharmacology and Toxicology, at Sunnybrook, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada